By Scott Gottlieb (Original source Fierce Biotech)
“Scott Gottlieb’s relatively short two-year tenure as the FDA’s head has ended, and we have a new man at the helm: Ned Sharpless. However, he used his first official talk to ensure we all know he’s not looking to tear up Gottlieb’s legacy.
Gottlieb, in fact, denied to reporters at the start of the year that he was leaving, but a few short months later he announced he was doing exactly that (citing commuting times), and then preceded to have the world’s longest goodbye tour. Fitting, I suppose, for a rock’n’roll FDA commissioner.
Gottlieb was praised by many in the bio Twitter sphere, as well as by President Donald Trump, the man who appointed him as FDA commissioner. Some areas, though, namely the opioid crisis and the surge in an anti-vaxxer movement, which has also seen a related spike in measles cases in the U.S., are still areas the FDA must get a grip on.”
Click here to see more
Niall Ferguson: Real Estate-ism Got the Deal Done in Gaza
Trump’s critics pine for old-school diplomacy. But Jared Kushner and Steve Witkoff triumphed where Joe Biden’s national security professionals failed. It has been a tough…
Thought Leader: Niall Ferguson
Niall Ferguson: The Disrupter in Chief’s Global Impact
No president has ever delivered so much so quickly. But Trump’s biggest challenge lies ahead in Xi Jinping’s China. The U.S. Constitution defines the president…
Thought Leader: Niall Ferguson
Dr. Sanjay Gupta: Why It Costs So Much to Get Sick
Since the 1990s, healthcare has been at the heart of America’s political debate and it’s still being contested today. Why is our health system so complicated? And how can we fix it? To help demystify it,…
Thought Leader: Sanjay Gupta
Scott Gottlieb on China’s biotech strategy
Thought Leader: Scott Gottlieb
Scott Gottlieb: China’s edge over U.S. biotech
Thought Leader: Scott Gottlieb
